论文部分内容阅读
目的:探讨丹参酮联合氯沙坦治疗矽肺并发肺心病心衰患者的疗效观察。方法:对94例矽肺并发肺心病、心衰患者随机分为对照组46例和观察组48例。对照组:给予抗感染,平喘,化痰止咳,强心,利尿等对症治疗,观察组:在常规治疗的基础上加用丹参酮80mg静点,氯沙坦50mg口服治疗,疗程均为15天,比较两组治疗前后心功能指标,BNP,肺动脉压改变情况。结果:观察组与对照组治疗后心功能指标,BNP,肺动脉压比较有统计学意义(P<0.05),观察组总有效率95.8%,高于对照组80.5%,差异有统计学意义(P<0.05)。结论:丹参酮联合氯沙坦治疗矽肺合并肺心病心衰的疗效显著,且无明显不良反应,值得临床推广。
Objective: To investigate the curative effect of tanshinone combined with losartan on patients with heart failure of silicosis and pulmonary heart disease. Methods: 94 patients with pulmonary heart disease and pulmonary heart disease were randomly divided into control group (46 cases) and observation group (48 cases). The control group was given anti-infective, antiasthmatic, phlegm and relieving cough, cardiac and diuretic symptomatic treatment. The observation group was treated with tanshinone 80mg intravenously and losartan 50mg orally on the basis of routine treatment for 15 days The changes of cardiac function, BNP and pulmonary artery pressure before and after treatment were compared between the two groups. Results: The cardiac function index, BNP and pulmonary arterial pressure in observation group and control group were statistically significant (P <0.05). The total effective rate was 95.8% in observation group and 80.5% in control group, with significant difference (P <0.05). Conclusion: The efficacy of tanshinone combined with losartan in the treatment of heart failure with silicosis complicated with pulmonary heart disease is remarkable, and no obvious adverse reactions are worthy of clinical promotion.